TY - JOUR
T1 - End-stage renal disease after pediatric heart transplantation
T2 - A 25-year national cohort study
AU - Choudhry, Swati
AU - Dharnidharka, Vikas R.
AU - Castleberry, Chesney D.
AU - Goss, Charles W.
AU - Simpson, Kathleen E.
AU - Schechtman, Kenneth B.
AU - Canter, Charles E.
N1 - Funding Information:
V.R.D. is a consultant for Bristol-Myers-Squibb and has received honoraria from Genzyme-Sanofi and grant support from Bristol-Myers-Squibb and Novartis. None of the other authors has a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose.
Funding Information:
This publication was funded by the Washington University in St. Louis Institute of Clinical and Translational Sciences, which is partly supported the National Institutes of Health/National Center for Advancing Translational Sciences, Clinical and Translational Science Award grant UL1-TR-000448. V.R.D. was partly supported by National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grant R01-DK-102981.
Publisher Copyright:
© 2018 International Society for the Heart and Lung Transplantation
PY - 2018/2
Y1 - 2018/2
N2 - Background: End-stage renal disease (ESRD), defined as the need for chronic dialysis and/or kidney transplantation (KTx), is a known complication after heart transplant (HTx). However, factors associated with ESRD are not well elucidated. The objectives of this study were to determine the prevalence, risk factors, and outcomes associated with ESRD after pediatric HTx. Methods: Scientific Registry of Transplant Recipients data were linked, using direct identifiers, to the United States Renal Data System to identify patients (aged ≤ 18 years) who underwent primary HTx between 1989 and 2013. Risk factors for ESRD and death were analyzed using Cox regression analysis. Results: Combining the above 2 databases identified ~25% additional HTx patients who developed ESRD that were not captured by either database alone. During a median follow-up of 11.8 years, ESRD developed in 276 of 6,901 patients (4%). The actuarial risk of developing ESRD after HTx was 3% at 10 years and 16% at 20 years. Age at HTx > 1 year, African-American race, year of HTx before 2000, hypertension, diabetes mellitus, re-HTx, acute dialysis, graft failure, and hospitalized infection were significant risk factors for ESRD development. Those who remained on chronic dialysis had higher risk of death than those who received KTx (hazard ratio, 31.4; 95% confidence interval, 20.8–48.4; p < 0.0001). Conclusions: ESRD after pediatric HTx is more prevalent in HTx survivors than documented by a transplant database alone. A number of factors develop at or after HTx that increase the risk for developing ESRD. Use of KTx in post-HTx ESRD is associated with improved survival.
AB - Background: End-stage renal disease (ESRD), defined as the need for chronic dialysis and/or kidney transplantation (KTx), is a known complication after heart transplant (HTx). However, factors associated with ESRD are not well elucidated. The objectives of this study were to determine the prevalence, risk factors, and outcomes associated with ESRD after pediatric HTx. Methods: Scientific Registry of Transplant Recipients data were linked, using direct identifiers, to the United States Renal Data System to identify patients (aged ≤ 18 years) who underwent primary HTx between 1989 and 2013. Risk factors for ESRD and death were analyzed using Cox regression analysis. Results: Combining the above 2 databases identified ~25% additional HTx patients who developed ESRD that were not captured by either database alone. During a median follow-up of 11.8 years, ESRD developed in 276 of 6,901 patients (4%). The actuarial risk of developing ESRD after HTx was 3% at 10 years and 16% at 20 years. Age at HTx > 1 year, African-American race, year of HTx before 2000, hypertension, diabetes mellitus, re-HTx, acute dialysis, graft failure, and hospitalized infection were significant risk factors for ESRD development. Those who remained on chronic dialysis had higher risk of death than those who received KTx (hazard ratio, 31.4; 95% confidence interval, 20.8–48.4; p < 0.0001). Conclusions: ESRD after pediatric HTx is more prevalent in HTx survivors than documented by a transplant database alone. A number of factors develop at or after HTx that increase the risk for developing ESRD. Use of KTx in post-HTx ESRD is associated with improved survival.
KW - dialysis
KW - end-stage renal disease
KW - kidney transplant
KW - pediatric heart transplant
KW - risk factors
UR - http://www.scopus.com/inward/record.url?scp=85031716030&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2017.09.027
DO - 10.1016/j.healun.2017.09.027
M3 - Article
C2 - 29055603
AN - SCOPUS:85031716030
SN - 1053-2498
VL - 37
SP - 217
EP - 224
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 2
ER -